Fig. 4: Genomic deletion and pharmacological inhibition of CCR1 in human and mouse ovarian cancer cells inhibits their migratory capacity toward CCL6/CCL23 in vitro. | Communications Biology

Fig. 4: Genomic deletion and pharmacological inhibition of CCR1 in human and mouse ovarian cancer cells inhibits their migratory capacity toward CCL6/CCL23 in vitro.

From: Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1

Fig. 4

a Immunofluorescence for CCR1 (red), cytokeratin (green), and nuclei (blue, DAPI) on ID8 cells metastasized to omentum in C57BL/6 and athymic nude mice (scale bar = 20 µm). b Immunofluorescence for CCR1 (red), EPCAM (green), and nuclei (blue, DAPI) on omenta derived from patients with high-grade serous cancer (scale bar = 20 µm). c, d Transwell migration assay of ID8 and SKOV3ip.1 with genomic deletion of CCR1 toward CCL6 and CCL23. e, f Transwell migration assay of ID8 and SKOV3ip.1 toward CCL6 and CCL23 with pharmacological inhibition of CCR1 using a small molecule antagonist UCB35625 (100 nM). Data shown represent mean and s.d of technical replicates (n = 3) for each condition. Statistical significance was determined by ordinary two-way ANOVA analysis comparing each condition to serum free (SF) media (**p < 0.005; ****p < 0.0001).

Back to article page